Novel NF-κB inhibitors: a patent review (2011-2014)

被引:26
作者
Arepalli, Sateesh Kumar [1 ]
Choi, Minho [1 ]
Jung, Jae-Kyung [1 ]
Lee, Heesoon [1 ]
机构
[1] Chungbuk Natl Univ, Coll Pharm, Cheongju 362763, South Korea
基金
新加坡国家研究基金会;
关键词
anti-inflammation; antitumor effects; immune responses; NF-kappa B inhibitors; HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSCRIPTION FACTOR; MICE LACKING; ACTIVATOR PROTEIN-1; PROSTATE CARCINOMA; CYSTEINE RESIDUES; IKK-ALPHA; CYCLIN D1; EXPRESSION; KINASE;
D O I
10.1517/13543776.2014.998199
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Importance of the field: The NF-kappa B family of transcription factors has a vital role in coordinating the expression of a wide variety of genes that control immune responses. The dysfunction of NF-kappa B has been associated with diseases ranging from inflammation to cancer. Areas covered: In this review, authors provided information on the role of NF-kappa B in human health and on recently developed inhibitors from patents granted in 2011 - 2014. The reader will gain an understanding of the mechanisms of NF-kappa B function as well as the structures and biological activities of recently developed NF-kappa B inhibitors. Expert opinion: Constitutive NF-kappa B activation is likely involved in the pathogenesis of several diseases. Researchers need to consider the specific mechanism of each invented NF-kappa B inhibitor, as well as the properties of the cellular, in vitro and in vivo assays and targeted diseases. For new drug development, they need various biological tests to assess the potential side effects and optimization of the biological activity.
引用
收藏
页码:319 / 334
页数:16
相关论文
共 181 条
[1]  
Ahn KS, 2012, Pharmaceutical composition for preventing or treating inflammatory diseases, allergic diseases or asthma, containing diospyros blancoi a. dc. extract as active ingredient, Patent No. [WO030137A2, 030137]
[2]  
Ahn KS, 2013, Pharmaceutical composition for preventing or treating inflammatory diseases, allergic diseases or asthma, containing diospyros blancoi a. dc. extract as active ingredient, Patent No. [US0164395A1, 0164395]
[3]  
Bacher A, 2012, Methods and compositions for inhibiting the nuclear factor kb pathway, Patent No. [WO011103A2, 011103]
[4]   The NF-kappa B and I kappa B proteins: New discoveries and insights [J].
Baldwin, AS .
ANNUAL REVIEW OF IMMUNOLOGY, 1996, 14 :649-683
[5]  
Baltimore D, 2012, Use of sam68 for modulating signaling through the tnf receptor, Patent No. [WO058642A2, 058642]
[6]  
Baltimore D, 1998, Nuclear factors associates with transcriptional regulation, Patent No. [US005804374, 005804374]
[7]  
Baschant U, 2011, Agent against glucocorticoid-induced osteoporosis, Patent No. [WO154413A1, 154413]
[8]  
Beg AA, 2013, Gene signature for the prediction of NFkappaB activity, Patent No. [WO067198A1, 067198]
[9]   The Dynamics of Signaling as a Pharmacological Target [J].
Behar, Marcelo ;
Barken, Derren ;
Werner, Shannon L. ;
Hoffmann, Alexander .
CELL, 2013, 155 (02) :448-461
[10]   Regulatory functions of ubiquitination in the immune system [J].
Ben-Neriah, Y .
NATURE IMMUNOLOGY, 2002, 3 (01) :20-26